Clinical oncology Flashcards
Who decides to start a complex oncology treatment for a newly diagnosed cancer patient?
A) The surgeon, because the tumor primarily requires resection
B) The oncologist, because he/she knows best about chemotherapy protocols
C) The pathologist, who determines the exact diagnosis using immunohistochemical methods
D) The radiotherapy specialist
E) All of the above
E) All of the above
What is the relationship between dysplasia and cancer?
A) Dysplasia always leads to the development of a cancer.
B) All cancer is preceded by dysplasia.
C) The progression of cancer is dysplasia.
D) A and C.
E) All of the above.
B) All cancer is preceded by dysplasia.
At cellular level tumor growth does not depend on the following:
A) time of cell cycle
B) growth fraction (proliferating tumor cell ratio)
C) cell death rate inside the tumor
D) time of duplication of tumor volume
E) apoptosis
E) apoptosis
The prognosis of the following tumor was the most significantly improved by combined chemotherapy:
A) Small cell lung cancer
B) Medulloblastoma
C) Seminoma
D) Neuroblastoma
C) Seminoma
Chemotherapy before surgery is important for the treatment of the following tumor:
A) Wilms-tumor
B) medulloblastoma
C) Burkitt-lymphoma
D) retinoblastoma
E) Gallbladder cancer
A) Wilms-tumor
After a curative surgery, the treatment for the prevention of recurrence:
A) neoadjuvant
B) adjuvant
C) palliative
D) supportive
E) none of the above
B) adjuvant
To evaluate the effectiveness of adjuvant treatment, the following parameter is chosen:
A) The time to relapse
B) Disease-free survival
C) Overall survival
D) All of the above
D) All of the above
In case of treatment of cancer patients, improvement of the disease is called:
A) remission
B) stable disease
C) progression
D) refractory disesase
E) none of the above
A) remission
Criteria for evaluating the therapeutic response during treatment of cancer patients:
A) Dukes-staging system
B) RECIST-staging system
C) Forrest-staging system
D) Bismuth-staging system
E) All of the above
B) RECIST-staging system
In oncological clinical studies progression free survival (PFS) is often evaluated. How do you define this term?
A) Progression-Free Survival (PFS) is the time that elapses in a progressive/metastatic tumor from starting treatment (from clinical trial randomization) to repeated tumor growth and/or death of a patient.
B) PFS is the time that elapses from the onset of the therapy of an advanced / metastatic disease (in clinical trials from randomization) to the death of a patient.
A) Progression-Free Survival (PFS) is the time that elapses in a progressive/metastatic tumor from starting treatment (from clinical trial randomization) to repeated tumor growth and/or death of a patient.
Definition of overall survival (OS):
A) Overall Survival (OS) is the time that elapses in a progressive / metastatic tumor from starting treatment (from randomization in clinical trials) to repeatedly confirmed tumor growth and / or death of the patient.
B) Overall survival (OS) is the time that elapses from the onset of tumor treatment (in clinical trials from randomization) to the death of a patient.
B) Overall survival (OS) is the time that elapses from the onset of tumor treatment (in clinical trials from randomization) to the death of a patient.
The overall response rate (ORR) is used to express the effectiveness of treatment in clinical trials. Which components does the ORR consist of? (CR is the complete response, PR is partial response, SD is stable disease / and PD is progressive disease /.)
A) ORR= CR+PR+ SD + PD
B) ORR= CR+PR+ SD
C) ORR= CR+PR
C) ORR= CR+PR
PRO abbreviation is often used in oncology drug development. It is the abbreviation of:
A) Progression Related Outcome
B) Patient Reported Outcome
B) Patient Reported Outcome
What is the RECIST criteria used for in oncology and in oncological clinical trials?
A) In solid tumors, the response to anticancer treatment in imaging studies is evaluated by these criteria.
B) RECIST relates to the determination of cell surface receptors in solid tumors.
A) In solid tumors, the response to anticancer treatment in imaging studies is evaluated by these criteria.
In ca. 10% of cancer patients, hypercalcaemia occurs due to tumor cells producing materials. Such materials are the following, except:
A) production of parathormon-like peptide
B) calcitonin
C) active metabolits of Vitamin-D
D) prostaglandins
E) TGF-α és TGF-β
B) calcitonin
Which gene’s defect is the most common in human tumors?
A) c-raf
B) c-myc
C) K-ras
D) p53
E) c-fos
D) p53
What is the meaning of MDR?
A) minimal disease residue
B) multiple drug resistance
C) maximal dose rate
D) mesenchymal disease risk
E) medulloblastoma gene receptor
B) multiple drug resistance
For which chemotherapeutic agent is the citrovorum factor or folic acid used as a “rescue” compound (for the protection of normal tissues and thus high dosage chemotherapy)?
A) methotrexat
B) bleomycin
C) cyclophosphamid
D) adriamycin
E) vincristin
A) methotrexat
Mesna may reduce the toxic damage of the bladder. Which cytostatic agent is it used for?
A) 5-fluorouracil
B) adriamycin
C) cisplatin
D) cyclophosphamid
E) methotrexat
D) cyclophosphamid
The following side effects may occur immediately or early after cytotoxic therapy except (indicate the exception):
A) nausea / vomiting
B) urocystitis
C) renal failure
D) phlebitis
E) azoospermia
E) azoospermia
Which phase of the cell cycle is affected by taxane type cytostatics?
A) G0
B) G1
C) S
D) G2
E) M
E) M
What is the machanism of action of camptothecin cytostatics (irinotecan, topotecan)?
A) inhibits the depolymerization of microtubules
B) topoizomerase II. inhibitors
C) topoizomerase I. inhibitors
D) Inhibition of DNA function and cell division in phase M
C) topoizomerase I. inhibitors
The following is valid for antimitotic chemotherapeutic drugs:
A) causes covalent crosslinking of the two polynucleotide chains in the dual spiral of DNA
B) they inhibit DNA synthesis through the inhibition of important enzymes of purine or pyrimidine synthesis.
C) they inhibit the polymerization of tubulins, i.e. the formation of mitotic spindles.
D) They inhibit the depolymerization of tubulins, i.e. blocking the mitotic spindle.
E) C and D
E) C and D
Which compound belongs to the strong opiates?
A) codein
B) oxycodon
C) tramadol
D) dextropropoxyphen
B) oxycodon